OCTA pushes for shorter interval between Sinovac, AstraZeneca doses

enablePagination: false
maxItemsPerPage: 10
totalITemsFound:
maxPaginationLinks: 10
maxPossiblePages:
startIndex:
endIndex:

FILE PHOTO

Metro Manila (CNN Philippines, July 28) -- OCTA Research fellow Nic Austriaco called on the government to shorten the period between doses of COVID-19 vaccines developed by China's Sinovac and British-Swedish firm AstraZeneca.

He said this is to boost vaccination rates amid concerns over the feared Delta variant.

Austriaco, a molecular biologist, proposed to reduce the two-dose interval for Sinovac to 14 days. Currently, the doses are given four weeks apart.

For the AstraZeneca shots, he suggested the period to be at eight weeks instead of extending it to 12. Based on the AstraZeneca vaccine's emergency use authorization, it should take four to 12 weeks before vaccinees receive their second dose.

Austriaco cited current evidence to back his proposal.

"The Turkish trial published in the Lancet two weeks ago showed 83.5% protection with a two-week interval. Though this was done with an earlier variant of SARS-CoV 2, it shows two doses are still effective," he said in a briefing.

"There are studies in many different populations that show an eight-week interval is protective," Austriaco added.